胰升糖素样肽-1受体激动剂在非危重住院患者血糖管理中的作用  

Glucagon-like peptide-1 receptor agonists and glycemic management in non-critical hospitalized patients

作　　者：刘明玉 李佳 Liu Mingyu;Li Jia(Department of Endocrinology and Metabolism,General Hospital of Guangzhou Military Command of PLA,People′s Liberation Army General Hospital of Southern Theatre Command,Guangzhou 510010,China)

机构地区：[1]中国人民解放军南部战区总医院内分泌科,广州510010

出　　处：《中华内分泌代谢杂志》2023年第5期460-466,共7页Chinese Journal of Endocrinology and Metabolism

基　　金：广东省中央引导地方科技发展专项基金(KTP20190249)。

摘　　要：近年来随着胰升糖素样肽-1受体激动剂(GLP-1RA)不断发展,其在住院患者血糖管理中的作用也不断被探索。GLP-1RA不仅能够良好地控制非危重住院患者血糖,还具有抑制食欲、延缓胃排空、保护神经、抗炎、降低收缩压及血脂等功能,同时多项研究发现其还可以改善心血管及肾脏结局,降低住院并发症风险。因此,本文通过复习近年来住院患者血糖管理相关国内外研究、共识和指南,分析GLP-1RA在非危重住院患者血糖管理方面的作用,有助于更好进行非危重住院患者血糖管理。In recent years,with the continuous development of glucagon-like peptide-1 receptor agonists(GLP-1RA),its role in the management of blood glucose in hospitalized patients has been explored.GLP-1RA can not only control blood glucose in non-critically ill hospitalized patients,but also inhibit appetite,delay gastric emptying,protect nerves,anti-inflammation,reduce systolic blood pressure and blood lipids.At the same time,many studies have found that it can also improve cardiovascular and renal outcomes and reduce the risk of hospitalization complications.Therefore,this paper analyzes the role of GLP-1RA in glycemic management by reviewing domestic and international studies,consensus and guidelines related to inpatient blood glucose management,and helps to better manage blood glucose of patients in non-critical care setting.

关 键 词：胰升糖素样肽-1 胰升糖素样肽-1受体激动剂 血糖管理 非危重住院患者 

分 类 号：R977.15[医药卫生—药品]